Clinical trial · Observational
Assessment of Updated Educational Materials for Instanyl®
Assessment of the Effectiveness of Updated Educational Materials on Prescribers' Knowledge and Behavior With Respect to Risks Associated With INSTANYL® Off-Label Use
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the Instanyl study is to learn how much doctors know and understand about Instanyl® before and after they receive updated educational information, including the risks of its unapproved use. In this study, the doctors will complete two surveys: one three months before they receive the updated educational information, and one about six months after they receive this information. They will answer questions about their prescribing behavior plus their knowledge of Instanyl® including any risks.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Pain | — | UNRESOLVED | — |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Prescribers of Instanyl®
- description
- Healthcare professionals (Oncologists, oncoradiologists, anaesthesiologists, pain management prescribers, palliative care prescribers, internal medicine prescribers, general practitioners and other specialties) who are current and potential prescribers of Instanyl® will be assessed before and after the distribution of the updated EMs via web-based survey questionnaire.
Primary outcomes (5)
- measure
- Percentage of Prescribers With Awareness of Updated Educational Materials (EMs) Based on Post-EM Questionnaire Survey
- timeFrame
- Up to 6 months (Post-EM Survey)
- measure
- Percentage of Prescribers With Change in Knowledge and Understanding of Key Safety Information Contained in Updated EMs Based on Pre-EM to Post-EM Questionnaire Survey
- timeFrame
- Up to 9 months (Pre-EM to Post-EM survey)
- measure
- Percentage of Prescribers With Change in Self-Reported Behavior Prescribing Based on Pre-EM to Post-EM Questionnaire Survey
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Specialists of any of those medical specialties targeted for the EMs as agreed with each national competent authority. The foreseen specialties include the following (subject to changes after the EM distribution plan is completed and agreed with national competent authorities): * Oncologists and oncoradiologists * Anaesthesiologists * Pain management prescribers * Palliative care prescribers * Internal medicine prescribers * General practitioner (GPs) * Other specialties may be locally included such as hematology. Current and potential prescribers may vary between country; thus, some countries may have modified lists of target specialties. 2. Physicians who have prescribed Instanyl® in the past 12 months (pre-EM survey) or since the updated EMs (post-EM survey) and who intend to prescribe Instanyl® in the following months after each survey. Exclusion Criteria: 1. Physicians who may have a conflict of interest (that is, prescribers employed by regulatory bodies, pharmaceutical industries). 2. Inactive or retired prescribers. 3. Physicians who did not prescribe Instanyl® in the past 12 months (pre-EM survey) or since the updated EMs are distributed (post-EM survey) and do not foresee treating a participants with Instanyl® in the following 12 months, regardless of whether they have prescribed Instanyl® before.
References
Publications (0)
Data not yet available